Zai Lab Limited
ZLABDrugs in Pipeline
10
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Dec 15, 2026
29wMarket Overview
Stock performance and key metrics
2 upcoming, 1 past
ZL-1310
Solid Tumors
Omadacycline
Community-acquired Bacterial Pneumonia
ZL-1109 (VRDN-003)
Thyroid Eye Disease (TED)
Investigator's Choice of Therapy
Small-cell Lung Cancer
DCC-2618
Gastrointestinal Stromal Tumors
ZL-2306(Niraparib）
Ovarian Cancer
ZL-3101
Eczema
Brivanib 800 mg, QD
Hepatocellular Carcinoma (HCC)
ZL-1102 1% w/w gel BID for 16 weeks
Plaque Psoriasis
Ripretinib
Gastrointestinal Stromal Tumor(GIST)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ZL-1310 | Phase 3 | Solid Tumors | - | - |
Omadacycline | Phase 3 | Community-acquired Bacterial Pneumonia | - | - |
ZL-1109 (VRDN-003) | Phase 3 | Thyroid Eye Disease (TED) | - | - |
Investigator's Choice of Therapy | Phase 3 | Small-cell Lung Cancer | - | - |
DCC-2618 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
ZL-2306(Niraparib） | Phase 2 | Ovarian Cancer | - | - |
ZL-3101 | Phase 2 | Eczema | - | - |
Brivanib 800 mg, QD | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
ZL-1102 1% w/w gel BID for 16 weeks | Phase 2 | Plaque Psoriasis | - | - |
Ripretinib | Phase 2 | Gastrointestinal Stromal Tumor(GIST) | - | - |